Company overview
Mission-Driven
Innovation
Innovation
CentryMed is a science-driven biopharmaceutical company committed to addressing global unmet medical needs through disruptive antibody innovation. We focus on developing first-in-class and best-in-class biologics that deliver real clinical impact for patients with cancer and autoimmune diseases.
Integrated R&D Ecosystem Across China and the U.S.
Leveraging dual-region advantages, we have built a full-cycle biologics R&D system—from antibody discovery to clinical
development. Our core R&D team has pioneered four proprietary platforms with global competitiveness:
development. Our core R&D team has pioneered four proprietary platforms with global competitiveness:
These platforms empower us to generate a pipeline with high diversity, functional precision, and translational efficiency.
-
Robust Pipeline with Global First-in-Class PotentialWe have established a differentiated pipeline of 20+ antibody programs, including monoclonal, bispecific, and trispecific formats. Several first-in-class assets have entered clinical trials and demonstrated:Encouraging signals of efficacy in advanced solid tumorsExcellent tolerability and safety profilesClear potential to fill critical gaps in current treatment landscapes -
International Talent and Scientific LeadershipOur R&D team consists of globally experienced scientists, with leadership drawn from top U.S. academic institutions and biotech companies. Under expert guidance, we continuously optimize platform design and product strategy to stay ahead of innovation trends. -
Recognition & AchievementsCentryMed is recognized as one of China's most innovative biotech companies. Notable achievements include:2nd Prize, National "Chuangke China" Innovation Competition1st Prize, China Innovation & Entrepreneurship Competition, Zhejiang DivisionOutstanding Project, National Disruptive Technology Innovation CompetitionRecognized as a “Specialized and Innovative” SME in ZhejiangNamed a Hangzhou Future Unicorn Company -
Strong Financial Backing & Global PartnershipsSince our founding in 2016, CentryMed has raised hundreds of millions of RMB across Series A to C funding rounds. We maintain strategic collaborations with top-tier global investors and are actively expanding our international footprint through:Licensing-out partnershipsCo-development opportunitiesIPO and capital market readiness
Looking Ahead
We are advancing the industrialization and globalization of antibody therapeutics. Our focus remains
on translating breakthrough science into meaningful clinical outcomes, delivering value to patients,
partners, and investors worldwide.
on translating breakthrough science into meaningful clinical outcomes, delivering value to patients,
partners, and investors worldwide.